Business Context and Reporting Period
This Form 8-K Current Report was filed by Acurx Pharmaceuticals, Inc. on March 9, 2026. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Staten Island, NY. The report details voluntary executive compensation reductions and a new clinical development initiative for its lead asset, ibezapolstat.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The financial impact is limited to the following compensation adjustments effective April 1, 2026:
- Executive Base Salaries: Reduced by 10% for the CEO, Executive Chairman, and CFO.
- Director Compensation: A 10% reduction to the cash component of non-employee director compensation, including annual retainers and committee fees.
Material Changes
There are no material changes to financial performance metrics reported in this filing. The primary material changes are operational and governance-related:
- Compensation Alignment: Implementation of voluntary salary reductions for key executives and cash retainer reductions for non-employee directors to align with market conditions and the operating plan.
- Clinical Expansion: Announcement of a new initiative to expand the ibezapolstat program into recurrent C. difficile infection (rCDI).
Guidance, Outlook, and Risks
Clinical Outlook: The Company plans an open-label pilot trial for rCDI enrolling up to 20 patients with multiply-recurrent infections. Trial start-up is scheduled for later in March 2026, with first-patient enrollment expected in the fourth quarter of 2026. Data from this study will inform a planned active-controlled Phase 3 registration trial. The Company intends to seek FDA approval under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD).
Risks and Contingencies: Forward-looking statements are subject to risks including the ability to achieve anticipated benefits from salary reductions, the ability to initiate and complete clinical trials on expected timelines, uncertainty of clinical trial results, and the ability to obtain regulatory approvals.
Investor Verification Checklist
- Verify the effective date of the 10% salary and director cash reductions (April 1, 2026).
- Confirm the timeline for the rCDI pilot trial start-up and first-patient enrollment (Q4 2026).
- Review the Company's 2025 10-K for the full details of the non-employee director compensation program referenced in this filing.
- Monitor subsequent filings for updates on the Phase 3 trial design based on the pilot study data.